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Interleukin 18 (IL-18) is a proinflammatory cytokine expressed by several cell types, including activated dendritic cells and
macrophages, that acts in synergy with IL-12 as an important amplifying factor for IFN- production and Th1 development.
To study the immunological and virological effects of IL-18 expression in the context of a lentiviral infection, we inoculated
rhesus macaques with a high dose of replication-competent simian immunodeficiency virus (SIV) vectors carrying the rhesus
IL-18 gene in the sense (SIVIL-18) or antisense (SIVFIGI) orientation. Both vectors behaved as attenuated viruses, resulting in low
viral loads, induction of low and transient levels of inflammatory cytokines, no CD4 T cell depletion, and mild activation of
T lymphocytes. Although IL-18-expressing virus could be isolated from some SIVIL18-infected macaques for 12 weeks
postinfection, the anti-SIV humoral and cellular immune responses of macaques inoculated with SIVIL18 and SIVFIGI were
similar to each other, with the exception of an early IFN- response in animals infected with SIVIL18. In summary, expression
of IL-18 during the acute phase of SIV infection does not increase viral replication or influence the outcome of the antiviral
immune response. © 2002 Elsevier Science (USA)INTRODUCTION
Interleukin-18, or interferon- inducing factor (IGIF), is
a proinflammatory cytokine that plays an important role
in the T cell helper type 1 (Th1) immune response,
primarily by its ability to induce interferon- (IFN-) pro-
duction in T cells and natural killer (NK) cells (Okamura
et al., 1995; Ushio et al., 1996). IL-18 is expressed by a
number of cells, including keratinocytes, osteoblasts,
pituitary gland cells, adrenal cortical cells, intestinal ep-
ithelial cells, and, more importantly, antigen-presenting
cells such as dendritic cells and activated macrophages
(Dinarello, 1999; Lebel-Binay et al., 2000). On the basis of
its primary structure, three-dimensional folding, receptor
family, signal transduction pathways, and biological ef-
fects, IL-18 appears to be a new member of the IL-1
family (Dinarello, 1999).
In the past few years, a large body of experimental
evidence has supported the notion of employing IL-18 as
an immune modulator, in synergy with IL-12, to enhance
the generation of cell-mediated immune responses. IL-18
has been delivered as a protein preparation or as plas-
mid DNA and has boosted immune responses against
cancer cells (Hara et al., 2000; Nagai et al., 2000; Ya-
manaka et al., 1999), pathogens (Kremer et al., 1999;
1 To whom correspondence and reprint requests should be ad-
dressed at Southwest Foundation for Biomedical Research, P.O. Box327Ohkusu et al., 2000), and subunit antigens (Eberl et al.,
2000). More importantly, delivery of plasmid DNA coding
for IL-18 has been shown to increase cell-mediated im-
mune responses in mice (Billaut-Mulota et al., 2000; Sin
et al., 1999) and in nonhuman primates (Kim et al., 1999).
These results make IL-18 an attractive candidate as a
cytokine with potential for enhancing the cellular im-
mune response to live-attenuated SIV vaccines. How-
ever, some recent publications demonstrated that IL-18
increased HIV-1 viral replication in cell lines (Klein et al.,
2000; Shapiro et al., 1998), suggesting that attenuation
could be jeopardized by IL-18 in the context of retroviral
replication. In this regard, we recently reported the clon-
ing of the rhesus macaque IL-18 gene and the construc-
tion of SIV vectors carrying this gene in the sense (SIVIL18)
and antisense (SIVFIGI) orientation. Although SIVIL18 ex-
pressed bioactive IL-18, we did not observe increased in
vitro viral replication in rhesus peripheral blood mono-
nuclear cell (PBMC) (Giavedoni et al., 2001). In this arti-
cle, we report that expression of IL-18 by SIV in vivo does
not result in increased viral replication. On the contrary,
SIV vectors containing the rhesus IL-18 gene are atten-
uated and result in mild infection, and the infected ani-
mals are able to mount very effective immune responses.
RESULTS
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al., 2001). SIVIL-18 contained the gene coding for the pre-
cursor form of the rhesus IL-18 protein in the sense
orientation, whereas SIVFIGI had the same nucleotide
sequences in the antisense orientation. SIVIL-18 ex-
pressed bioactive IL-18 in rhesus PBMC, while SIVFIGI
served as a control that had similar genomic modifica-
tions and expressed no bioactive molecules. Twelve rhe-
sus macaques were chosen by the ability of their PBMC
to support SIV replication. Animals were divided into two
groups of six monkeys each, with each group consisting
of three male and three female monkeys of similar age
and weight. Animals in one group were inoculated with
104 TCID50 of SIVFIGI iv, whereas macaques in the other
group received the same dose of SIVIL18.
Primary infection of rhesus macaques with SIV
vectors
Macaques were intensively studied during the early
phase of viral infection. Plasma samples were used for
the determination of SIVp27, IL-4, IL-18, GM-CSF, IFN-
/, and IFN-; lymph node (LN) biopsies were per-
formed at 0, 2, 4, and 12 weeks postinfection (WPI). Data
generated from this study were compared with our find-
ings in rhesus macaques of similar age and genetic
origin that were inoculated with a lower dose (100
TCID50) of pathogenic SIV (Giavedoni et al., 2000). Ani-
mals infected with recombinant SIV vectors had cell-
associated viral loads in LN cells that were almost 100
times lower at 2 WPI than the ones observed in ma-
caques infected with wild-type SIV; by 4 WPI, viral loads
in these monkeys were similar to the ones observed at 2
WPI and comparable to the viral loads seen in wild-type
infected monkeys at the same time point. Finally, by 12
WPI, viral loads reached a very low set-point (Fig. 1A),
and virus isolation from the blood of macaques inocu-
lated with the SIV vectors became sporadic from that
time point forward (data not shown). Another striking
difference with animals infected with pathogenic SIV was
that macaques inoculated with SIV vectors did not show
the classical peak of plasma IL-18 at 2 WPI, even for
those animals infected with SIVIL18 (Fig. 1B). Macaques
infected with SIVIL18 and SIVFIGI also showed a transient
peak of IFN/ at 2 WPI, a delay of 1 week compared
with macaques infected with SIVmac251 (Fig. 1C). Levels of
SIVp27, GM-CSF, IL-4, and IFN- in plasma of macaques
infected with SIVIL-18 and SIVFIGI were below the limit of
detection of the enzyme-linked immunosorbent assay
(ELISA) tests at all time points.
Similarly, infection with SIVIL18 and SIVFIGI did not result
in the dramatic changes in the level of LN CD4 and
CD8 T lymphocytes usually seen in macaques infected
with SIVmac251 (Figs. 2A and 2B). Interestingly, macaques
infected with SIV vectors did show the same pattern of
NK cell activation seen in animals infected with patho-
genic SIV (Fig. 2C). However, activation of CD4 and
CD8 T cells in LN, measured as upregulation of CD69,
was marginal (Figs. 3A and 3C). Histological evaluation
of LNs during the same period showed mild classical
changes associated with SIV infection with minimal to
moderate hyperplasia that subsided by 12 WPI (data not
shown). Activation of T lymphocytes in the peripheral
blood of macaques infected with SIV vectors followed
similar curves to the ones observed in animals infected
with virulent SIV, although the percentage of activated
cells was much lower (Figs. 3B and 3D). For example,
upregulation of CD69 on T cells of macaques after infec-
tion (2 WPI) was seen for both monkeys infected with
SIVIL18 (P values of 0.025 and 0.005 for CD4
 and CD8
T cells, respectively) as well as monkeys infected with
SIVFIGI (P values are 0.048 and 0.0214 for CD4
 and CD8
T cells, respectively).
In summary, primary infection of rhesus monkeys with
FIG. 1. Viral loads in lymph node cells and plasmatic cytokines in rhesus macaques after infection with SIV vectors. Rhesus macaques were
infected with 104 TCID50 of SIVFIGI (closed circles) or SIVIL-18 (open triangles). (A) Cell-associated viral loads were determined in LNC by limited dilution
and cocultivation with CEM-x-174 cells. (B) IL-18 concentration was measured by ELISA. (C) IFN--induced antiviral activity was detected in plasma
by a biological assay as described under Materials and Methods. Values represent the mean of six animals, with standard deviation. As a comparison,
similar measurements from four macaques infected with 102 TCID50 of SIVmac251 are included (closed squares) (Giavedoni et al., 2000).
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SIVIL18 was indistinguishable from infection with SIVFIGI
since both resulted in low viral loads and very mild
cellular and inflammatory changes. Thus, expression of
IL-18 by SIV in vivo does not increase viral loads or
lymphocyte activation.
Viral species isolated from infected animals
Virus was isolated from the LN of rhesus macaques at
different time points after infection and the 3 LTR of the
isolated proviral DNA was characterized by PCR with
FIG. 2. Changes in lymphocyte phenotype after infection with SIV vectors. Rhesus macaques were infected with SIVFIGI (closed circles) or SIVIL-18
(open triangles). Minimal changes were observed in CD4 and CD8 CD3 cell levels in lymph nodes (A and B, respectively), and for activation of
NK cells (CD3CD16CD56) in peripheral blood (C). As a comparison, similar measurements from macaques infected with SIVmac251 are included
(closed squares) (Giavedoni et al., 2000). Cells were identified by flow cytometry as described under Materials and Methods. Values represent the
mean with the standard deviation.
FIG. 3. Mild activation of CD3 T cells after infection with SIV vectors. Changes in the level of expression of the activation marker CD69 on CD4
(A and B) and CD8 (C and D) T cells present in lymph nodes (A and C) or peripheral blood (B and D) were determined by flow cytometry. Animals
were infected with SIVFIGI (closed circles) or SIVIL-18 (open triangles). Similar measurements from macaques infected with SIVmac251 are included (closed
squares) (Giavedoni et al., 2000).
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primers that bound to SIV regions surrounding the site
where the IL-18 gene had been inserted. The superna-
tant of these cocultures was also evaluated for the pres-
ence of IL-18 by an ELISA specific for the biologically
active molecule (Shida et al., 2001; Taniguchi et al., 1997)
and the KG-1 biological assay (Konishi et al., 1997). By 2
WPI, viruses isolated from macaques infected with SIVIL18
and SIVFIGI showed the presence of full-length IL-18 gene
inserts, although the appearance of viral species in
which the insert was being deleted was already evident
(Fig. 4). By 4 WPI, the accumulation of viruses that were
losing the IL-18 gene insert was more evident, even
though bioactive IL-18 continued to be expressed. By 12
WPI, three of the four macaques inoculated with SIVIL18
from which virus could be isolated still expressed bioac-
tive IL-18. Finally, by 16 WPI all the isolated viruses had
lost the IL-18 gene insert (data not shown).
Thus, SIV vectors inevitably lose their IL-18 gene in-
serts and evolve into species that have an average
“wild-type virus” size genomes. There was a tendency for
a more rapid deletion of the inserted sequences in ani-
mals inoculated with SIVFIGI than in macaques infected
with SIVIL18. This phenomenon has been observed before
and it seems related to a particularly unstable arrange of
nucleotides in the viral genome rather than a direct effect
of the cytokine being expressed (Giavedoni et al., 1997).
At all time points, IL-18 expression and activity was found
only in the supernatant of positive cultures from SIVIL18-
infected animals, indicating that PBMC or LN cells from
which nonrecombinant SIV is isolated in vitro do not
normally release IL-18.
Immune responses of rhesus macaques to SIV
vectors
The cellular and humoral SIV-specific immune re-
sponses of the inoculated macaques were evaluated by
different methodologies. Humoral immune responses
were determined by antigen-specific ELISA (Fig. 5). Both
anti-gp160 and anti-Gag antibodies were detected in
some animals by 4 WPI and in all monkeys by 8 WPI and
reached high and stable levels by 12 WPI. Differences in
FIG. 4. Characterization of proviral DNA in lymph node cells from macaques infected with SIVIL18 or SIVFIGI. Virus isolated by cocultivation of LN cells
and CEM-x-174 cells was characterized by PCR as described under Materials and Methods. PCR products were separated in a 1% agarose gel. MWM:
100-bp ladder. The supernatant of each coculture was assayed for the presence of IL-18 by ELISA and the KG-1 biological assay as described under
Materials and Methods.
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titers between animals infected with SIVFIGI or SIVIL18
were not statistically significant, indicating that antibody
responses were not affected by expression of IL-18.
Proliferative immune responses specific for SIV were
determined at 24 and 40 WPI against SIV Gag virus-like
particles produced in insect cells by a recombinant bac-
ulovirus, using VSV nucleocapsid as a control antigen
(Fig. 6). A two-tailed, two-sample unequal variance t test
analysis of the data obtained at 24 WPI showed that,
after stimulation with SIV Gag, cells from macaques
inoculated with SIVIL18 released more IFN- than cells
from monkeys infected with SIVFIGI (P  0.036). The
same type of analysis on samples obtained at 40 WPI
showed that the SIV Gag-specific expression of IFN-
was not statistically significant between the two groups
of animals (P  0.493). As a control, the same cells
exposed to the superantigens Staphylococcus entero-
toxin A and B showed similar levels of expression of
IFN- at 24 WPI (P  0.534) and 40 WPI (P  0.630).
We developed a nonradioactive killing assay using
overlapping peptides to identify SIV Gag-specific CTL
epitopes in animals infected with SIVIL18 and SIVFIGI (Fig.
FIG. 5. Humoral immune responses of macaques inoculated with SIV
vectors. Titer of antibodies specific for SIV Env (top row) or SIV Gag
(bottom row) were determined by antigen-specific ELISA as described
under Materials and Methods.
FIG. 6. Proliferation of macaque PBMC. PBMC from macaques inoculated with SIVIL18 or SIVFIGI were harvested at 24 or 40 weeks postinoculation
and exposed to either SIV Gag, vesicular stomatitis virus nucleoprotein (VSV-N), or the superantigens SEA and SEB. After 6 days in culture, IFN- was
quantitated in the supernatant by ELISA and the cellular content was determined by DNA concentration. The value for wells containing VSV-N was
subtracted from the values for SIV Gag and SEA/B.
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7). This technique allowed us to identify CTL epitopes in
9 of the 12 macaques infected with the recombinant
viruses. These reactive peptides were then used in IFN-
ELISPOT assays to monitor the progression of the cellu-
lar immune response during SIV infection. Spot-forming
cells (SFC) were found in animals from both groups, with
notable intragroup animal-to-animal variation, and re-
mained stable during the first 10 months of infection.
Similarly, number of spots also varied for the same ani-
mal during time, with no correlation with viral loads. No
statistically significant differences were observed when
comparing the number of IFN- SFC from animals inoc-
ulated with SIVIL18 or SIVFIGI (data not shown).
Hence, with the exception of an early IFN- immune
response found in SIVIL18-infected monkeys, anti-SIV hu-
moral and cellular immune responses were similar for
macaques infected with either SIVIL18 or SIVFIGI.
DISCUSSION
The current perception in the field of AIDS vaccine
development is that a candidate immunogen will have to
elicit both strong and long-lasting CTLs and broadly
neutralizing antibodies (Nabel, 2001). Live-attenuated vi-
ruses are the type of vaccines that have provided the
best examples of protection in the SIV/macaque model
(Daniel et al., 1992; Giavedoni et al., 1997; Joag et al.,
1998; Johnson et al., 1999; Silverstein et al., 2000; Vil-
linger et al., 2000). However, reports of residual patho-
genicity (Baba et al., 1999; Wyand et al., 1997) and po-
tential for recombination of the vaccine virus with chal-
lenge virus (Gundlach et al., 2000) have reduced the
original enthusiasm and made the prospect of such vac-
cine for humans almost impractical. Nevertheless, the
study of host–pathogen interactions between rhesus ma-
caques and attenuated SIV offers an excellent opportu-
nity for identifying immune correlates for protection that
could be applied to other vaccines. In general, live-
attenuated vaccines have shown a direct correlation
between virulence and immunogenicity (Desrosiers et
al., 1998; Johnson and Desrosiers, 1998). Therefore, we
decided to explore ways to increase immunogenicity
without compromising attenuation. Cytokines have been
shown to serve as natural adjuvants in several experi-
mental settings in nonhuman primates, for example, in-
creasing the immunogenicity of DNA vaccines or chang-
ing the type of the induced immune response (Barouch et
al., 2000; Kim et al., 1999). We have previously employed
SIV as an expression vector for cytokines and showed
FIG. 7. Nonradioactive cell killing assay. B-LCL cells were stained with CFDA, incubated with SIV Gag peptides (pools of eight peptides or individual
peptides), and exposed to stimulated autologous monkey PBMC. After a 4-h incubation, cells were stained with propidium iodide (PI), washed, and
run in a flow cytometer. A first gate was created around the B-LCL. A second gate selected for CFDA-stained B-LCL. Finally, gated cells were analyzed
in CFDA versus PI dot-plots. Spontaneous killing was determined in the absence of effector cells. Maximum killing consisted of target cells treated
with saponin. The example shows PBMC from macaque 14305 killing autologous B-LCL that had been incubated with either SIV Gag peptide pool
F (peptides 43 to 50, NIH AIDS Research and Reference Reagent Program), peptide 43 (DHVMAKCPDRQAGFLGLGPW), or reactive peptide 44
(QAGFLGLGPWGKKPRNFPMA).
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that the expression of IFN- by SIV resulted in an atten-
uated virus that induced low and transient viral loads in
rhesus macaques (Giavedoni et al., 1997). However, that
study compared the infectivity of the SIV vector express-
ing IFN- (SIVHyIFN) with the parental virus SIVnef, and
those two viruses had different genome lengths and
ability to replicate in rhesus PBMC (Giavedoni and Yilma,
1996). The possibility that the in vivo attenuation ob-
served for the SIV vector expressing IFN- was due to its
intrinsic difficulty for replication, rather than the biologi-
cal activity of the cytokine being expressed, was not
evaluated. In the present study we compared two viruses
with identical genome length which differed only in the
orientation of the inserted rhesus IL-18 gene and, there-
fore, in their capacity to express bioactive IL-18. Thus,
differences in the virological and immunological out-
comes of infection of rhesus macaques with SIVIL18 or
SIVFIGI would reflect the consequences of precursor IL-18
protein expression by SIV. Our results here show that
both SIVIL18 and SIVFIGI replicated at low levels in the
infected animals, similarly to the slow in vitro replication
observed in rhesus PBMC (Giavedoni et al., 2001). Virus
isolated from macaques inoculated with SIVIL18 during
the peak of viremia still expressed bioactive IL-18, dem-
onstrating that expression of the proinflammatory cyto-
kine IL-18 in vivo did not result in increased SIV replica-
tion. However, due to this limited viral replication, we did
not observe an increase in plasma levels of IL-18 in
animals inoculated with SIVIL18 compared with the con-
centration observed in macaques inoculated with SIVFIGI.
In fact, as another indication of limited viral spread and
replication, animals inoculated with both SIV vectors had
undetectable levels of SIVp27 in plasma.
In a recent study, we reported that infection of rhesus
macaques with pathogenic SIVmac251 induced the accu-
mulation of IFN-/ and IL-18 in plasma and that NK
activity paralleled changes in viral loads (Giavedoni et
al., 2000). We now describe that macaques of similar
genetic background, sex, and age, inoculated with a
larger dose of SIV vectors carrying the IL-18 gene, have
a very different plasma cytokine profile. For example, the
peak of IFN-/, although still present, was detectable
only at 2 WPI, and there was no increment in the con-
centration of IL-18 during this acute phase. However,
activation of NK cells was very similar to the one seen in
monkeys infected wild pathogenic virus. Since both
IFN- and IL-18 are cytokines released by dendritic cells
and stimulated macrophages that induce activation of
NK cells during viral infections (Matikainen et al., 2001;
Sareneva et al., 1998), our findings indicate that IFN-
may be a more relevant mediator of the innate immune
response during SIV infection. Additionally, we demon-
strate that macaques inoculated with SIVIL18 or SIVFIGI
show no statistically significant changes in the level of
CD69 expression on CD4 or CD8 T cells in LNs and
that the transient activation of CD8 T cells in peripheral
blood may reflect the expansion of CTL that usually
controls the primary SIV infection (Kuroda et al., 1999). All
these findings add to the notion that these SIV vectors
are very attenuated and that expression of IL-18 has a
limited role on SIV replication.
The influence of IL-18 expression by SIV on the gen-
eration of an anti-SIV immune response was very mod-
est. IL-18 has been shown to act synergistically with
IL-12 in generating Th1 immune responses to DNA-en-
coded antigens (Billaut-Mulota et al., 2000; Kremer et al.,
1999; Sin et al., 1999) and proteins (Eberl et al., 2000).
However, it was recently demonstrated in mice that ab-
errant expression of IL-18 resulted in increased produc-
tion of both Th1 and Th2 cytokines (Chan et al., 2001) and
that IL-18 induced the differentiation of Th1 or Th2 cells
depending upon cytokine milieu and the genetic back-
ground of the animals (Xu et al., 2000). These findings
have led to the understanding that the functions of IL-18
in vivo are very heterogeneous and complicated; in prin-
ciple, IL-18 enhances the IL-12-driven Th1 immune re-
sponses, but it can also stimulate Th2 immune re-
sponses in the absence of IL-12 (Nakanishi et al., 2001).
In our experimental model, although IL-18-expressing
virus was rescued from three of six animals inoculated
with SIVIL18 for over 3 months, their humoral or cellular
immune responses were not that different from those
detected in the other SIVIL18- or SIVFIGI-infected ma-
caques. The only distinguishable and measurable effect
of IL-18 expression by SIV on the immune response was
an early in vitro IFN- response to SIV Gag in animals
inoculated with SIVIL18. Then again, despite this IFN-
response, anti-SIV Gag antibodies and CTL activities
measured at identical time points were similar for ani-
mals inoculated with SIVIL18 or SIVFIGI.
It is important to mention that both SIVIL18 or SIVFIGI lack
nef coding sequences. The nef gene product of SIV has
several biological features, such as downregulation of
the CD3 -chain, CD4, CD28, and class I MHC expres-
sion, and association with many intracellular proteins
(reviewed in Geyer et al., 2001) that may affect directly or
indirectly the generation of an immune response. There-
fore, another possibility to explain our results is that
infection with slow replicating viruses that lack nef ex-
pression allows the macaque’s immune system to mount
an efficient response, which is not affected by the low
expression level of IL-18.
In summary, we demonstrated that recombinant SIV
vectors that carry the IL-18 gene in either direction be-
have similar to live-attenuated viruses in vivo, resulting in
low viral loads, efficient antiviral immune response, and
lack of generalized cell activation. Expression of IL-18, a
proinflammatory cytokine known to increase HIV replica-
tion in vitro, did not result in increased SIV replication or
in any other detectable change in virological and immu-
nological parameters. Perhaps the expression by SIV of
other cytokines with a more potent and direct effect on
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the immune system, such as IL-12, may have a more




The construction and characterization of the replica-
tion-competent SIV vector expressing rhesus IL-18 has
been described elsewhere (Giavedoni et al., 2001).
Briefly, SIVIL18 and SIVFIGI are SIVmac239 viruses with a
deletion in the nef gene and with an insertion of the
rhesus macaque IL-18 gene that codes for the precursor
protein in the sense and antisense orientation, respec-
tively. CEM-x-174 cells, rhesus PBMCs, and lymph node
cells were used for SIV isolation and propagation. These
cells, and the NK-sensitive human erythroblastoid cell
line K562, were maintained in RPMI 1640 supplemented
with 10% fetal calf serum, 2 mM glutamine, 0.1 mg/ml
streptomycin, and 100 U/ml penicillin (Cellgro Media-
tech, Herndon, VA) [RPMI-10]. Human A549 cells were
propagated in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5% fetal bovine serum and
antibiotics. Encephalomyocarditis virus (EMCV), used for
the antiviral assay of IFN in plasma, was propagated in
human A549 cells.
Infection of rhesus macaques
Twelve colony-bred, weight-, sex-, and age-matched
rhesus macaques (Macaca mulatta) were used in this
experiment. Animals were seronegative for simian type
D retroviruses, simian T cell leukemia virus, and SIV. The
animals were used and cared for in accordance with the
American Association for Accreditation of Laboratory An-
imal Care Guidelines, and protocols were approved by
the SFBR Institutional Animal Care and Use Committee
(IACUC). Six macaques (14303, 14304, 14307, 14309,
14311, and 14312) were inoculated iv with 1 ml of RPMI
1640 containing 104 TCID50 of SIVIL18. The remaining an-
imals (14301, 14302, 14305, 14306, 14308, and 14310)
received 104 TCID50 of the control virus SIVFIGI. Each
group consisted of three male and three female mon-
keys.
Measurements in plasma
Plasma p27 antigenemia was measured by a commer-
cial SIV core antigen capture ELISA (Coulter Corp., Hi-
aleah, FL) as instructed by the manufacturer (sensitivity
of 50 pg/ml). Levels of GM-CSF, IL-4, IL-12, and IFN-
were determined with commercially available ELISA kits
(kits for GM-CSF and IL-4 were from Immunotech, Miami,
FL, and Cytoscreen Monkey IFN- and IL-12 were from
BioSource, Camarillo, CA). The limits of detection were 5
pg/ml for GM-CSF and IL-4, and 4 pg/ml for IFN- and
IL-12. Plasma levels of IL-18 were determined with an
ELISA kit kindly provided by H. Okamura (Hyogo College
of Medicine and Hayashibara Corp., Japan), as de-
scribed before (Taniguchi et al., 1997); the monoclonal
antibodies of this ELISA kit only recognize bioactive IL-18
with a sensitivity of 10 pg/ml (Shida et al., 2001). Plasma
IFN activity was determined by measuring inhibition of
the cytopathic effect caused by EMCV infection in A549
cells (Giavedoni et al., 1992). IFN- was also determined
in plasma with a commercial kit (PBL Biomedical Labo-
ratories, New Brunswick, NJ).
LN biopsies
Peripheral LN (axillary and/or inguinal) were obtained
by transcutaneous biopsy under ketamine HCl anesthe-
sia (10 mg/kg im; Parke-Davis, Morris Plains, NJ) prior to
and at 2, 4, and 12 WPI. LN were divided aseptically into
two fractions for single-cell preparation and pathological
analysis. Lymphocyte suspensions were obtained by
mechanical teasing of tissues. The fractions for patho-
logical analysis were fixed in 10% neutral buffered for-
malin, processed conventionally, cut at 5 m, and
stained with hematoxylin and eosin (H&E) for routine
histological examination. Tissues were examined
blinded for changes in lymphoid architecture and cellu-
larity.
Cell-associated viral loads
Cell-associated virus, latent or productive, was mea-
sured by limiting-dilution assay of LN cells cocultured
with CEM-x-174 cells in 24-well plates (Van Rompay et
al., 1992). Twice weekly, culture media were assayed for
the presence of the SIV major core protein (p27) by
ELISA (Lohman et al., 1991). Virus levels were calculated
according to the method of Reed and Muench (1938) and
expressed as TCID50 per 10
6 cells. Cell-free supernatants
were tested for IL-18 biological activity on KG-1 cells as
described before (Giavedoni et al., 2001).
Isolation of proviral DNA
Proviral DNA was extracted from 1  106 LNC, PBMC,
or CEM-x-174 cells and amplified by PCR with primers
specific for the SIV 3 region. Primers for PCR amplifica-
tion were H (sense primer, 5CTCTCTGCGACCCTACA-
GAGG3, nt 9272 of SIV) and E (5AAATCCCTTCCAGTC-
CCCCC3, antisense, nt 9710 of SIV). Nucleic acids were
denatured at 94°C for 1 min, annealed at 65°C for 1 min,
and extended at 72°C for 2 min; this cycle was repeated
35 times. PCR products were resolved in 1% agarose
gels. DNA fragments generated by this reaction were
870 nt in length for viruses containing the intact IL-18
gene insert, 460 nt for wild-type SIV, and 280 nt for SIVnef,
respectively.
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Lymphocyte phenotyping
Phenotypic characterization of PBMC and LNC was
performed by flow cytometry using three-color direct
immunofluorescence as described before (Giavedoni et
al., 2000). Absolute values for cells in whole blood were
obtained by combining the percentages obtained by flow
cytometry with the values of total white blood cell count
per microliter and the differential formula for each animal
at each time point.
Anti-SIV antibodies
Plasma samples were analyzed for the presence of
antibodies reactive to SIV envelope glycoproteins and
p27 core protein. Antigens for ELISA plates were ob-
tained from a viral preparation of SIVmac239 concen-
trated by 20% sucrose cushion centrifugation. Protein
content of the viral preparation was determined with the
CBQCA Protein Quantification Kit (Molecular Probes, Eu-
gene, OR). Anti-gp160 antibodies were quantitated with
lysed SIV particles and concavalin A coated plates as
previously described (Cole et al., 1997; Robinson et al.,
1990). For the anti-SIV p27 antibody ELISA, the same
disrupted, envelope-depleted viral preparation was
added to ELISA plates previously coated with anti-SIV
p27 antibodies (Lohman et al., 1991).
Proliferation assay
Proliferative responses of rhesus lymphocytes to dif-
ferent antigens were tested in vitro. Rhesus PBMC were
isolated and seeded into a round-bottom polypropylene
96-well plate at a density of 1  105 in 200 l RPMI 10
medium. PBMC were stimulated for 6 days in the pres-
ence of SIVgag VLPs (3 g/ml), vesicular stomatitis virus
nucleoprotein (VSV N) (3 g/ml), or Staphylococcus en-
terotoxin A and B (SEA/B) (0.5 g/ml). On day 6, super-
natant (150 l) was harvested to test for cytokine pro-
duction by an in-house IFN- ELISA. Volume was re-
stored by adding back 150 l RPMI and then an aliquot
(20 l) of the cell suspension was removed to determine
cell density by a fluorescent DNA quantitation assay
(CyQUANT cell proliferation assay, Molecular Probes).
The IFN- ELISA plates were prepared by coating Immu-
lon II plates with 5 g/ml of a murine mAb anti-human
IFN- (clone MD-1, Biosource) in PBS. ELISA plates were
coated for 3 h at 37°C, washed four times with 0.05%
Tween-20-PBS, and blocked with blotto overnight at 4°C.
Plates were washed again and 100 l of supernatant and
standards were loaded and incubated for 2 h at 37°C.
Plates were washed and a 1:1000 dilution of a biotinyl-
ated rabbit polyclonal anti-IFN- antibody (BioSource,
100 l/well) was added and incubated for 1 h at 37°C.
After washing, plates were incubated with streptavidin-
horseradish peroxidase (Bio-Rad, Richmond, CA) for 30
min at room temperature. After a final wash, plates were
developed with 100 l of TM-Blue substrate and stopped
with 100 l 2 N H2SO4. The OD of each was measured at
450 nm in an automated plate reader (HTS 7000 Bio
Assay Reader, Perkin–Elmer, Branchburg, NJ).
Cytotoxic T lymphocyte assays
Autologous lymphoblastoid B cell lines (B-LCL) were
prepared at the initiation of this study for each animal by
infection of rhesus PBMC with herpes papio virus in the
presence of cyclosporin A. A set of 48 peptides that span
the whole SIVmac239 Gag protein, each 20 amino acids
long and with a 10 amino acid overlap between sequen-
tial peptides (obtained from the NIH AIDS Research and
Reference Reagent Program), were divided into six pools
of eight continuous peptides. Rhesus PBMC were resus-
pended at 8  106 cells/ml in RPMI-10 and added in
aliquots of 250 l to six wells of a 48-well plate. Peptide
pools were added to the cells at 10 g/ml and cultured at
37°C for 48 h. On the third day, recombinant human IL-2
(a generous gift of Hoffmann-La Roche, Inc.) was added
at 50 U/ml, and cells were kept in culture for a total of 14
days with the addition of fresh IL-2-containing medium
twice per week. B-LCL (2  106 cells) were then treated
with 50 g/ml mitomycin C for 30 min at 37°C, washed
thoroughly, divided in six aliquots of 2  105 each, and
mixed with the different peptide pools for 90 min at 37°C.
These B-LCL/peptide mixtures were used to stimulate
autologous PBMC for an additional 3-day period. Finally,
stimulated PBMC were purified by Ficoll–Hypaque cen-
trifugation, counted, and tested in a flow cytometry killing
assay, using B cell lines coated with SIV Gag peptide
pools as the target. The day before the killing assay,
B-LCL were washed with plain RPMI, resuspended at
5  107 cells/ml, and stained with 0.5 M of 5- (and
6-)carboxy-fluorescein diacetate succinimidyl ester
(CFDA, Molecular Probes) at 37°C for 10 min. The reac-
tion was stopped with cold RPMI 10 and the B-LCL were
incubated overnight at 37°C. The following morning,
CFDA-labeled B-LCL were counted, divided into seven
aliquots, and incubated with the different SIV Gag pep-
tide pools for 90 min at 37°C. Stimulated PBMC were
counted, added to CFDA-labeled B-LCL at different ef-
fector/target ratios, and incubated at 37°C for 4 h. At the
end of the incubation, propidium iodine (PI) was added to
each tube at 1 g/ml, incubated at 37°C for 15 min,
washed with 0.1% BSA in PBS, and analyzed by flow
cytometry. The acquisition was performed with a first
gate created around the B-LCL in a forward versus side-
scatter dot-plot. A second gate was created for CFDA-
positive cells in a forward-scatter versus FL-1 dot-plot.
Finally, cells were analyzed in a FL-1 (FITC) versus FL-3
(PI) dot-plot, using B-LCL that had not been exposed to
PBMC or that were treated with saponin to draw the
spontaneous or maximum killing regions, respectively.
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ELISPOT
Rhesus PBMC were seeded at 1–2  105 cells in 100
l of RPMI 10 in IFN- ELISPOT plates (U-Cytech,
Utrecht, The Netherlands), and reactive or control SIV
Gag peptides were added in duplicate at 10 g/ml. After
a 24-h incubation at 37°C, cells were lysed and plates
were developed according to the manufacturer’s instruc-
tions. Spots were counted and the difference between
the number of spots for the reactive peptide minus the
number of spots for the peptide control was multiplied by
10 and referred to as spot-forming cells (SFC)/106 PBMC.
Statistical analyses
The two-sample t test for samples with unequal vari-
ances was implemented in the commercially available
computer program SYSTAT, v.9.0 (SPSS, Inc., Chicago, IL).
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